Innovative Therapeutics Anacor's focus on novel small-molecule therapeutics derived from boron chemistry offers unique opportunities for partnerships in dermatology and infectious disease areas, particularly in topical antifungal and anti-inflammatory treatments.

Established Pipeline With multiple clinical-stage compounds and key assets licensed to major players like GlaxoSmithKline, there is potential to expand licensing or co-development agreements for later-stage assets or new indications.

Financial Position Although the company's revenue is modest at $25-50 million, its substantial funding of $250 million indicates strong backing for growth, making it attractive for collaborations aimed at accelerating clinical development or commercialization.

Market Alignment Positioned within the pharmaceutical manufacturing sector with a focus on topical and systemic infectious and inflammatory therapies, Anacor's portfolio complements larger pharma companies seeking innovative dermatology and antimicrobial solutions.

Strategic Acquisition Having been acquired by Pfizer in 2016 for $5.2 billion, there may be continued interest in acquiring or licensing promising assets or technologies, offering opportunities for business development with companies looking to strengthen their infectious disease or dermatology pipelines.